Secular trends in neuroblastoma mortality before and after the cessation of national mass screening in Japan

Journal of Epidemiology

Volumn 19, Issue 5, 2009, Pages 266-270

  Katanoda, Kota ^a   Hayashi, Kunihiko ^b   Yamamoto, Keiko ^b   Sobue, Tomotaka ^a  

^a NATIONAL CANCER CENTER   (Japan)

^b GUNMA UNIVERSITY   (Japan)

Author keywords

Mass screening; Mortality; Neuroblastoma

Indexed keywords

ADOLESCENT; ADRENAL TUMOR; ARTICLE; CHILD; HUMAN; INFANT; JAPAN; MASS SCREENING; MORTALITY; NEUROBLASTOMA; NEWBORN; PRESCHOOL CHILD; REGRESSION ANALYSIS; SECULARISM;

ADOLESCENT; ADRENAL GLAND NEOPLASMS; CHILD; CHILD, PRESCHOOL; HUMANS; INFANT; INFANT, NEWBORN; JAPAN; MASS SCREENING; MORTALITY; NEUROBLASTOMA; REGRESSION ANALYSIS; SECULARISM;

EID: 70349574067     PISSN: 09175040     EISSN: 13499092     Source Type: Journal    
DOI: 10.2188/jea.JE20090037     Document Type: Article

References (22)

1. Schilling FH, Spix C, Berthold F, Erttmann R, Fehse N, Hero B, et al. Neuroblastoma screening at one year of age. N Engl J Med. 2002;346:1047-53.
2. Woods WG, Gao RN, Shuster JJ, Robison LL, Bernstein M, Weitzman S, et al. Screening of infants and mortality due to neuroblastoma. N Engl J Med. 2002;346:1041-6.
3. Ajiki W, Tsukuma H, Oshima A, Kawa K. Effects of mass screening for neuroblastoma on incidence, mortality, and survival rates in Osaka, Japan. Cancer Causes Control. 1998;9:631-6.
4. Hiyama E, Iehara T, Sugimoto T, Fukuzawa M, Hayashi Y, Sasaki F, et al. Effectiveness of screening for neuroblastoma at 6 months of age: a retrospective population-based cohort study. Lancet. 2008;371:1173-80.
5. Honjo S, Doran HE, Stiller CA, Ajiki W, Tsukuma H, Oshima A, et al. Neuroblastoma trends in Osaka, Japan, and Great Britain 1970-1994, in relation to screening. Int J Cancer. 2003;103:538-43.
6. Nishi M, Miyake H, Takeda T, Hanai J, Kikuchi Y, Takasugi N. Mass screening for neuroblastoma and mortality in birth cohorts. Int J Cancer. 1997;71:552-5.
7. Suita S, Tajiri T, Akazawa K, Sera Y, Takamatsu H, Mizote H, et al. Mass screening for neuroblastoma at 6 months of age: difcult to justify. J Pediatr Surg. 1998;33:1674-8.
8. Yamamoto K, Ohta S, Ito E, Hayashi Y, Asami T, Mabuchi O, et al. Marginal decrease in mortality and marked increase in incidence as a result of neuroblastoma screening at 6 months of age: cohort study in seven prefectures in Japan. J Clin Oncol. 2002;20:1209-14.
9. Matsumura M, Tsunoda A, Nishi T, Nishihira H, Sasaki Y. Spontaneous regression of neuroblastoma detected by mass screening. Lancet. 1991;338:447-8.
10. Nishihira H, Toyoda Y, Tanaka Y, Ijiri R, Aida N, Takeuchi M, et al. Natural course of neuroblastoma detected by mass screening: s 5-year prospective study at a single institution. J Clin Oncol. 2000;18:3012-7.
11. Okazaki T, Kohno S, Mimaya J, Hasegawa S, Urushihara N, Yoshida A, et al. Neuroblastoma detected by mass screening: the Tumor Board's role in its treatment. Pediatr Surg Int. 2004;20:27-32.
12. Oue T, Inoue M, Yoneda A, Kubota A, Okuyama H, Kawahara H, et al. Prole of neuroblastoma detected by mass screening, resected after observation without treatment: results of the Wait and See pilot study. J Pediatr Surg. 2005;40:359-63.
13. Yamamoto K, Hanada R, Kikuchi A, Ichikawa M, Aihara T, Oguma E, et al. Spontaneous regression of localized neuroblastoma detected by mass screening. J Clin Oncol. 1998;16:1265-9.
14. Yoneda A, Oue T, Imura K, Inoue M, Yagi K, Kawa K, et al. Observation of untreated patients with neuroblastoma detected by mass screening: a "wait and see" pilot study. Med Pediatr Oncol. 2001;36:160-2.
15. Tsubono Y, Hisamichi S. A halt to neuroblastoma screening in Japan. N Engl J Med. 2004;350:2010-1.
16. Hanawa Y, Sawada T, Tsunoda A. Decrease in childhood neuroblastoma death in Japan. Med Pediatr Oncol. 1990;18:472-5.
17. Nishi M, Takeda T, Hatae Y, Hanai J, Fujita K, Ichimiya H, et al. Contribution of HPLC mass screening for neuroblastoma to a decrease in mortality. J Exp Clin Cancer Res. 2002;21:73-8.
18. Hayashi K, Fujita T, Katanoda K, Sobue T, Sato T, Nishi M, et al. Effectiveness of mass-screening program on neuroblastoma mortality in 1995-2000 birth cohort of Japan: Nationwide Neuroblastoma Mortality Study. Advances in Neuroblastoma Research 2004, Genoa, Italy.
19. Hayashi K. Epidemiologic evaluation of mass screening program for neuroblastoma. In: Kuroda Y, ed. Research on effective implementation and development of mass screening, Research on Measures for Intractable Diseases, Health and Labour Sciences Research Grants, 2004: 109-165.
20. Day N. Cumulative rate and cumulative risk. In: Muir C, Waterhouse J, Mack T, Powell J, Whelan S, editors. Cancer Incidence in Five Continents Volume V. Lyon: International Agency for Research on Cancer; 1987. p. 787-789.
21. Kim HJ, Fay MP, Feuer EJ, Midthune DN. Permutation tests for joinpoint regression with applications to cancer rates. Stat Med. 2000;19:335-51.
22. Panel on Mass Screening Program for Neuroblastoma Ministry of Health, Labour and Welfare. A report on the mass screening program for neuroblastoma, 2003.